Breast最新文献

{"title":"Corrigendum to \"Current pattern of care in radiation therapy for DCIS in Australia - where are we heading?\" [The Breast 82(2025) 104482].","authors":"Adam Ofri, Sze Ki Melanie Tam, Suki Gill, Andrew J Spillane","doi":"10.1016/j.breast.2025.104582","DOIUrl":"https://doi.org/10.1016/j.breast.2025.104582","url":null,"abstract":"","PeriodicalId":9093,"journal":{"name":"Breast","volume":" ","pages":"104582"},"PeriodicalIF":7.9,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145181786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Baseline tumour burden and prognosis in breast cancer treated with immune checkpoint inhibitors","authors":"Julia Dixon-Douglas ,&nbsp;Lauren C. Brown ,&nbsp;Kate Moodie ,&nbsp;Courtney T. Van Geelen ,&nbsp;Steven David ,&nbsp;Prudence A. Francis ,&nbsp;Peter Savas ,&nbsp;Sherene Loi","doi":"10.1016/j.breast.2025.104586","DOIUrl":"10.1016/j.breast.2025.104586","url":null,"abstract":"<div><h3>Background</h3><div>Immune checkpoint inhibitors (ICI), alone or in combination with other agents, are now standard of care for a range of tumour types, including breast cancer. Radiological assessment of baseline tumour burden has been associated with prognosis in a variety of tumour types treated with immunotherapeutic agents. Whether baseline tumour burden is prognostic in breast cancer treated with ICI is unknown.</div></div><div><h3>Methods</h3><div>A retrospective review of patients from a single institution with advanced breast cancer treated with ICI was performed. The sum of baseline target lesion measurements (baseline tumour size [BTS]) and all lesions (total tumour burden [TTB]) were determined in accordance with RECIST version 1.1 and correlated with clinical outcomes.</div></div><div><h3>Results</h3><div>82 patients were identified, treated between 2015 and 2020. BTS and TTB by quartile were significantly associated with overall survival (OS) (p &lt; 0.001) and clinical benefit rate at 6 months (CBR6) in univariable analysis (p = 0.004 and p = 0.002 for BTS and TTB, respectively). Multivariable analysis confirmed a significant inverse relationship with OS for both BTS (p = 0.035) and TTB (p = 0.024). A non-statistically significant numerical inverse association between increasing tumour burden and progression free survival was also observed.</div></div><div><h3>Conclusion</h3><div>Baseline tumour burden assessed by BTS and TTB is significantly associated with prognosis in advanced breast cancer treated with ICI and should be considered a potential biomarker to improve selection of patients for treatment with ICI. These results suggest that ICI treatment will be most effective in patients with lower tumour burden.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"84 ","pages":"Article 104586"},"PeriodicalIF":7.9,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145205588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigating the prognostic role of citrullination-related genes in breast cancer by combining transcriptomics, single-cell analysis and verification","authors":"Weijie He ,&nbsp;Shanji Fan ,&nbsp;Yongmei Luo ,&nbsp;Xinyu Yi ,&nbsp;Yingjie Liu ,&nbsp;Guicheng He ,&nbsp;Zhimin Li ,&nbsp;Yuehua Li","doi":"10.1016/j.breast.2025.104588","DOIUrl":"10.1016/j.breast.2025.104588","url":null,"abstract":"<div><div>Citrullination, a process linked to autoimmune diseases, has been implicated in cancer, but its role in breast cancer (BRCA) remains unclear. This study aimed to identify citrullination-related genes (CRGs) associated with prognosis in BRCA. We utilized datasets from The Cancer Genome Atlas (TCGA-BRCA) and Gene Expression Omnibus (GEO), pinpointing candidate genes by intersecting differentially expressed genes (DEGs) from TCGA-BRCA with known CRGs. Prognostic CRGs were selected using univariate Cox regression and Lasso regression analyses, and a predictive nomogram was created based on independent prognostic factors identified through multivariate Cox regression. Our findings revealed that SEZ6, S100B, SPIB, and TFF1 were key CRGs used to construct a risk model. High-risk BRCA patients exhibited immune-suppressive tumor microenvironments (TMEs) with low CD8⁺ T cell mutation and enrichment in C1/C4 immune subtypes. In contrast, low-risk patients displayed high immune infiltration and enrichment in C2/C3/C6 subtypes. High expression of S100B, SPIB, and TFF1 was associated with increased immune infiltration by NK cells and T cells, while high SEZ6 expression was linked to neutrophil mutations, PD-L1 upregulation, and low CD8⁺ T cell infiltration. Molecular docking studies explored the interactions of these CRGs with entinostat. In conclusion, SEZ6, S100B, SPIB, and TFF1 were identified as significant prognostic genes in BRCA, providing insights into BRCA pathogenesis and potential personalized treatment strategies.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"84 ","pages":"Article 104588"},"PeriodicalIF":7.9,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145211660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FDA and EMA approval of datopotamab-deruxtecan: A paradigm shift in breast cancer drug evaluation?","authors":"Armando Orlandi","doi":"10.1016/j.breast.2025.104589","DOIUrl":"10.1016/j.breast.2025.104589","url":null,"abstract":"<div><div>The January 2025 FDA and EMA approvals of datopotamab-deruxtecan for metastatic HR-positive, HER2-negative breast cancer represents an unprecedented regulatory decision. The TROPION-Breast01 trial demonstrated significant progression-free survival improvement (6.9 vs 4.9 months; HR 0.63) but failed to show overall survival benefit (18.6 vs 18.3 months; HR 1.01)[1,2]. This marks the first full approval of a breast cancer therapeutic that failed a co-primary overall survival endpoint. Subsequently, the European Medicines Agency also granted marketing authorization in January 2025, creating a concerning precedent across both major regulatory agencies. With both major regulatory agencies now having approved this agent, breast cancer specialists must grapple with fundamental questions: What constitutes meaningful clinical benefit in heavily pretreated patients? How should we interpret trials with divergent endpoint results? This commentary examines the implications for breast cancer practice and argues for urgent reassessment of evidence standards as the therapeutic landscape evolves.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"84 ","pages":"Article 104589"},"PeriodicalIF":7.9,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145156081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Complete responders in patients with HER2-positive metastatic breast cancer: a real-world SONABRE study","authors":"Nan Ding ,&nbsp;Renee Visserman ,&nbsp;Sandra M.E. Geurts ,&nbsp;Jolien Tol ,&nbsp;Birgit E.P.J. Vriens ,&nbsp;Kirsten N.A. Aaldering ,&nbsp;Eline Boon ,&nbsp;Marcus W. Dercksen ,&nbsp;Franchette van den Berkmortel ,&nbsp;Manon J.A.E. Pepels ,&nbsp;Natascha A.J.B. Peters ,&nbsp;Joan B. Heijns ,&nbsp;Linda van de Winkel ,&nbsp;Aude J.O. de Fallois ,&nbsp;Vivianne C.G. Tjan-Heijnen ,&nbsp;Maaike de Boer","doi":"10.1016/j.breast.2025.104583","DOIUrl":"10.1016/j.breast.2025.104583","url":null,"abstract":"<div><h3>Background</h3><div>We aimed to describe real-world complete response (CR) rates, predictors of CR, and survival outcomes in patients treated with first-line pertuzumab, trastuzumab, and chemotherapy for HER2-positive (HER2+) metastatic breast cancer (MBC).</div></div><div><h3>Methods</h3><div>Patients with HER2+ MBC who started first-line pertuzumab, trastuzumab, and chemotherapy in 2013–2021 were selected from the SONABRE Registry (NCT-03577197), involving eleven Dutch hospitals. CR was defined as no evidence of disease on imaging during first-line systemic therapy with or without local therapy (surgery and/or radiotherapy). Multivariable logistic regression was used to identify predictors for CR. Progression-free survival (PFS) and overall survival (OS) from the start of first-line pertuzumab, trastuzumab, and chemotherapy were computed with the Kaplan-Meier method.</div></div><div><h3>Results</h3><div>We included 244 patients treated with first-line pertuzumab, trastuzumab, and chemotherapy, with a median follow-up duration of 71 months (interquartile range: 60–82 months). A CR during first-line systemic therapy was reached in 63 patients (26 %). Patients younger than 65 years (odds ratio (OR) = 5.24, 95 %CI:1.49–18.44, p = 0.01), those with <em>de Novo</em> MBC (OR = 2.48, 95 %CI:1.24–4.93, p = 0.01), or those with a single metastatic site (OR = 3.81, 95 %CI:1.83–7.96, p &lt; 0.001) were more likely to reach CR than their counterparts. The 5-year PFS and OS rates were, respectively, 63 % (95 %CI:48 %–75 %) and 85 % (95 %CI:72 %–92 %) in patients with a CR and 10 % (95 %CI:6 %–16 %) and 36 % (95 %CI:28 %–44 %) in patients without a CR.</div></div><div><h3>Conclusions</h3><div>In the real world, one in four patients treated with first-line pertuzumab, trastuzumab, chemotherapy, with or without local therapy, reached CR. Two third of patients with a CR were still free of progression after five years.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"84 ","pages":"Article 104583"},"PeriodicalIF":7.9,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145156510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Hormonal factors predictive of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in POSITIVE trial” [The Breast 83 (2025) 104547]","authors":"Isabelle Demeestere ,&nbsp;Samuel M. Niman ,&nbsp;Ann H. Partridge ,&nbsp;Daniela S. Diego ,&nbsp;Roswitha Kammler ,&nbsp;Monica Ruggeri ,&nbsp;Marco Colleoni ,&nbsp;Chikako Shimizu ,&nbsp;Cristina Saura ,&nbsp;Karen A. Gelmon ,&nbsp;Anna B. Saetersdal ,&nbsp;Judith R. Kroep ,&nbsp;Audrey Mailliez ,&nbsp;Frederic Amant ,&nbsp;Manuel Ruız-Borrego ,&nbsp;Jeong Eon Lee ,&nbsp;Akemi Kataoka ,&nbsp;Janice M. Walshe ,&nbsp;Junko Takei ,&nbsp;Simona Borstnar ,&nbsp;Fedro A. Peccatori","doi":"10.1016/j.breast.2025.104570","DOIUrl":"10.1016/j.breast.2025.104570","url":null,"abstract":"","PeriodicalId":9093,"journal":{"name":"Breast","volume":"84 ","pages":"Article 104570"},"PeriodicalIF":7.9,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145109195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and molecular characteristics of HER2-low triple-negative breast cancer: insights from multi-omics analysis","authors":"Yinlong Yang ,&nbsp;Liangwei Pan ,&nbsp;Wenzhe Zhou ,&nbsp;Zhimin Shao","doi":"10.1016/j.breast.2025.104584","DOIUrl":"10.1016/j.breast.2025.104584","url":null,"abstract":"<div><h3>Background</h3><div>The emergence of novel human epidermal growth factor receptor 2 (HER2)-targeting drugs has provided a new therapeutic option for HER2-low triple-negative breast cancer (TNBC) patients who had limited treatment choices previously. However, the biological implications and prognostic significance of HER2-low status in TNBC are still not fully appreciated.</div></div><div><h3>Methods</h3><div>Utilizing a single-center multi-omics cohort of TNBC patients that includes whole exome sequencing and RNA sequencing data, this study aims to explore the clinical and molecular characteristics between HER2-low and HER2-0 TNBC.</div></div><div><h3>Results</h3><div>The study comprised 207 patients with HER2-low TNBC and 153 patients with HER2-0 TNBC. Findings revealed that HER2-low tumors exhibited lower tumor grade, more nodal involvement and lower Ki-67 index compared to HER2-0 tumors. Additionally, HER2-low TNBC were associated with more mutations in PIK3CA and its corresponding pathways, a more prominent clock-like mutation signature, along with activation of androgen receptor (AR)-related pathways and fatty acid metabolism. While HER2-low status did not significantly influence recurrence-free survival (RFS) across the entire study population, HER2-low patients showed significant better RFS compared to HER2-0 patients within the luminal androgen receptor (LAR) subtype. This distinction was also evident at molecular level.</div></div><div><h3>Conclusion</h3><div>HER2-low TNBC demonstrated unique clinical, transcriptomic and genomic characteristics when contrasted with HER2-0 TNBC. In the LAR subtype, a clear molecular and prognostic discrepancy between HER2-0 and HER2-low tumors was identified.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"84 ","pages":"Article 104584"},"PeriodicalIF":7.9,"publicationDate":"2025-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145119478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early decision regret and its relationship with decision participation among breast cancer patients undergoing surgery","authors":"Qinqin Cheng ,&nbsp;Qianlin Jiang ,&nbsp;Xi Chen ,&nbsp;Xiaobo Hu ,&nbsp;Mingzhi Xia ,&nbsp;Yingchun Jiao","doi":"10.1016/j.breast.2025.104585","DOIUrl":"10.1016/j.breast.2025.104585","url":null,"abstract":"<div><h3>Purpose</h3><div>Decision regret is a negative emotion that persistently impacts the patients’ quality of life and future decision-making process. This study aimed to explore the early decision regret among breast cancer patients undergoing surgery and its relationship with their perceived importance and actual participation in decision-making.</div></div><div><h3>Methods</h3><div>A cross-sectional study was conducted from August 2024 to March 2025. Breast cancer patients undergoing surgery were recruited by convenience sampling. All the participants completed the decision regret scale and the questionnaire measuring perceived importance of participation and the degree of participation in decision-making about treatment, in one month after they received surgery.</div></div><div><h3>Results</h3><div>A total of 213 breast cancer patients undergoing surgery participated in this study. Among them, 85.4 % (n = 182) experienced early decision regret, with 43.2 % of them (n = 92) having a low level of decision regret and 42.2 % (n = 90) having a high level of decision regret. Their decision regret was significantly associated with their actual participation in decision-making (B = 8.246, 95 % CI: 2.037–14.455, <em>p</em> = 0.009). but not with their perceived importance of participation. The lower the extent of participation in decision-making, the higher the level of decision regret.</div></div><div><h3>Conclusion</h3><div>The majority of the breast cancer patients receiving surgery experienced early decision regret. It is associated with their actual participation in decision-making. Promoting breast cancer patients’ participation in their own decision-making, such as patient-centered communication and a shared decision-making model, may have the potential to alleviate their regrets about their early decisions.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"84 ","pages":"Article 104585"},"PeriodicalIF":7.9,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145156509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of cardiotoxicity following breast cancer irradiation in an Asian cohort in real-world settings","authors":"Wen-Chi Yang ,&nbsp;Yu-Hsuan Chen ,&nbsp;Chia-Chun Wang ,&nbsp;Shih-Fan Lai ,&nbsp;Szu-Huai Lu ,&nbsp;Li-Ting Ho ,&nbsp;Chiun-Sheng Huang ,&nbsp;Sung-Hsin Kuo","doi":"10.1016/j.breast.2025.104581","DOIUrl":"10.1016/j.breast.2025.104581","url":null,"abstract":"<div><h3>Background</h3><div>Adjuvant radiotherapy (RT) for early-stage breast cancer is associated with increased major cardiovascular (CV) events. This study investigates cardiac toxicity in an Asian breast cancer cohort, focusing on the interplay between RT, cardiovascular risk factors, and systemic treatments, a topic less explored in regions with lower cardiovascular disease (CVD) prevalence.</div></div><div><h3>Methods</h3><div>Patients with breast cancer who underwent adjuvant RT between January 2004 and November 2014 were included in this single-institutional retrospective study. Patients were categorized by CVD risk factors, including obesity, smoking history, prior CVD incidents, chronic kidney disease (CKD), diabetes mellitus, hypertension, and dyslipidemia. The primary outcome was the incidence of major CV events, defined as conditions requiring intervention, including heart failure, arrhythmia, and ischemic heart disease. Kaplan–Meier methods, log-rank tests, and Cox regression models were used for statistical analysis.</div></div><div><h3>Results</h3><div>Among the 975 patients, the 10-year cumulative incidence of major CV events was 3.7 %, with no significant difference (p = 0.892) between right-sided (3.8 %) and left-sided RT (3.4 %). Patients with low, intermediate, and high CVD risk factors had 10-year cumulative incidences of 0.7 %, 2.5 %, and 13.7 %, respectively. Multivariate analysis revealed that hypertension, CKD, and previous CVD were significantly associated with major CV events. In patients without CVD risk factors, the 10-year incidence of CV events was higher in those undergoing left-sided RT compared to right-sided RT (1.3 % vs. 0.0 %, p = 0.032).</div></div><div><h3>Conclusions</h3><div>Major CV events incidences following RT in this Asian cohort with low baseline CVD risk were modest. However, the impact was more pronounced in patients without baseline CVD risk factors, emphasizing the need for personalized risk assessment in RT planning.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"84 ","pages":"Article 104581"},"PeriodicalIF":7.9,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145119479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and validation of a next-generation sequencing-based method for calculating the breast cancer polygenic risk score PRS313","authors":"Flora Ponelle-Chachuat ,&nbsp;Mathis Lepage ,&nbsp;Sandrine Viala ,&nbsp;Mikaïl Kelleci ,&nbsp;Edith Le Floch ,&nbsp;Claire Dandine-Roulland ,&nbsp;Delphine Bacq ,&nbsp;Robert Olaso ,&nbsp;Jean-François Deleuze ,&nbsp;Nancy Uhrhammer ,&nbsp;Mathilde Gay-Bellile ,&nbsp;Yannick Bidet ,&nbsp;Maud Privat","doi":"10.1016/j.breast.2025.104580","DOIUrl":"10.1016/j.breast.2025.104580","url":null,"abstract":"<div><div>Polygenic risk scores (PRS) are genetic tools that quantify an individual's predisposition to certain diseases by combining the effects of many genetic variants. The PRS₃₁₃ includes 313 genomic variants and has been incorporated into the BOADICEA prediction model and in the CanRisk software to refine breast cancer risk. However, its current implementation relies on SNP microarrays, limiting its use in sequencing-based clinical workflows.</div><div>In this study, we directly compared SNP microarray technology and targeted NGS sequencing to determine the PRS₃₁₃. The two methods were tested for 154 patients. To replace PRS₃₁₃ SNPs with low sequencing coverage and/or in regions of low complexity, 27 proxy SNPs in high linkage disequilibrium were integrated into the panel. After this optimization, the NGS-derived PRS₃₁₃ demonstrated strong concordance with the microarray reference (R² = 0.95), with sensitivity and specificity reaching 96 % and 97 %, respectively. Moreover, the clinical risk category, as defined by CanRisk, remained consistent in 97 % of cases across both methods.</div><div>These findings validate the use of targeted NGS for PRS₃₁₃ calculation, demonstrating its feasibility, accuracy, and potential for easy integration into routine oncogenetic workflows. By enabling PRS calculation from the same sequencing data used for gene panel testing, this approach eliminates the need for separate genotyping platforms, offering a cost-effective and clinically practical solution to support the broader implementation of personalized breast cancer risk prediction.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"84 ","pages":"Article 104580"},"PeriodicalIF":7.9,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145102555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}